You are here

Article Text

Article menu
Download PDFPDF
Practice guideline
Observational study
New ACC-AHA cholesterol guidelines significantly increase potential eligibility for statin treatment
  1. Vera Bittner
  1. Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA
  1. Correspondence to : Professor Vera Bittner, Division of Cardiovascular Disease, University of Alabama at Birmingham, 701 19th Street South, LHRB 310, Birmingham, AL 35294, USA; vbittner{at}uab.edu

https://doi.org/10.1136/ebmed-2014-110029

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Pencina MJ, Navar-Boggan AM, D’Agostino RB Sr., et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014;370:1422–31.OpenUrlCrossRefPubMedWeb of Science

    Context

    In 2013, new guidelines for the treatment of cholesterol for the prevention of cardiovascular disease (CVD) were issued by the American College of Cardiology and the American Heart Association (ACC-AHA), based on a systematic review of lipid lowering trials and meta-analyses evaluating treatment impact on CVD morbidity and mortality, and quantitated adverse effects of lipid-lowering therapy.1 Many of these trials were reported after publication of the NIH-issued Third Adult Treatment Panel (ATPIII) lipid-lowering guidelines.2 The new guidelines feature modified eligibility criteria for cholesterol-lowering treatment based on estimation of benefits and harms of therapy in specific population subsets, and recommend use of a new risk calculator which …

    View Full Text

    Footnotes

    • Competing interests VB is an investigator in clinical trials sponsored by Sanofi-Aventis/Regeneron, Amgen, Pfizer, Janssen, GlaxoSmithKline, Bayer Healthcare, AstraZeneca and Merck. She has consulted for Amarin and Novartis.

    • Provenance and peer review Commissioned; internally peer reviewed.